| 孟 鑫,陶维静,徐晓璋,等.68Ga-ADAPT6 PET/CT代谢参数与乳腺癌HER2表达相关性研究[J].肿瘤学杂志,2025,31(11):973-978. |
| 68Ga-ADAPT6 PET/CT代谢参数与乳腺癌HER2表达相关性研究 |
| Correlation Between 68Ga-ADAPT6 PET/CT Metabolic Parameters and HER2 Expression in Breast Cancer |
| 投稿时间：2024-12-25 |
| DOI：10.11735/j.issn.1671-170X.2025.11.B007 |
|
 |
| 中文关键词: 乳腺肿瘤 人表皮生长因子受体 2 镓 白蛋白结合域衍生亲和蛋白6 PET/CT |
| 英文关键词:breast neoplasms human epidermal growth factor receptor 2 Ga albumin-binding domain-derived affinity protein 6 PET/CT |
| 基金项目:吴阶平医学基金会临床科研专项资助基金（320.6750.2022-19-42；320.6750.2023-18-71）；南京医科大学部省共建肿瘤个体化医学协同创新项目（2024CICCPMHR017） |
|
| 摘要点击次数: 7 |
| 全文下载次数: 2 |
| 中文摘要: |
| 摘 要：［目的］ 探讨正电子发射体层成像（positron emission tomography，PET）/计算机体层成像（computed tomography， CT）显像剂镓68标记的白蛋白结合域衍生亲和蛋白6（albumin-binding domain-derived affinity protein 6，68Ga-ADAPT6）预测乳腺癌患者人表皮生长因子受体 2（human epidermal growth factor receptor 2， HER2）表达状态的临床价值。［方法］ 研究纳入2023年11月至2024年10月于南京医科大学附属淮安第一人民医院经病理确诊乳腺癌26例女性患者，治疗前行 18氟代脱氧葡萄糖（18F-fluorodeoxyglucose， 18F-FDG）及68Ga-ADAPT6 PET/CT全身扫描。根据免疫组织化学及荧光原位杂交检测结果，分为HER2高表达、低表达及零表达三组，比较各组间临床资料及PET/CT代谢参数，包括最大标准化摄取值（maximum standardized uptake value， SUVmax）、最大瘦体标准化摄取值（maximum standardized uptake value normalized by lean body mass， SULmax）、肿瘤总糖酵解值以及肿瘤HER2靶向总摄取量。采用Spearman相关分析评估各代谢参数与HER2表达的相关性，并采用受试者工作特征曲线分析代谢参数对HER2表达的鉴别效能。［结果］ 68Ga-ADAPT6代谢参数中，HER2高表达组SUVmax［6.70（5.12，12.39）］显著高于HER2低表达组（4.65±2.27）、零表达组（3.34±1.59），差异具有统计学意义（P<0.05）；HER2高表达组SULmax ［5.11（3.67，8.66）］显著高于HER2低表达组（3.27±1.42）、零表达组（2.38±1.16），差异具有统计学意义（P<0.05）；但HER2低表达与HER2零表达组SUVmax、SULmax差异均无统计学意义（P均>0.05）。HER2表达与68Ga-ADAPT6 代谢参数SUVmax、 SULmax间呈正相关性（r=0.616、0.646，P均<0.001）。68Ga-ADAPT6 SUVmax最佳截断值为5.22，预测HER2高表达的灵敏度为80.0%，特异度达75.0%。68Ga-ADAPT6 SULmax最佳截断值为3.44，预测HER2高表达的灵敏度为70.0%，特异度达91.7%。［结论］ 68Ga-ADAPT6 PET/CT在评估乳腺癌患者的HER2表达状态上具有一定的应用价值，未来有望成为筛查靶向治疗获益人群的潜在影像学手段。 |
| 英文摘要: |
| Abstract：［Objective］ To evaluate the clinical value of 68Ga-labeled albumin-binding domain-derived affinity protein 6 (68Ga-ADAPT6) as a positron emission tomography/computed tomography (PET/CT) imaging agent in predicting human epidermal growth factor receptor 2 (HER2) expression status in breast cancer patients. ［Methods］ From November 2023 to October 2024， 26 female patients with pathologically confirmed breast cancer at The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University were enrolled. All patients underwent whole-body 18F-fluorodeoxyglucose (18F-FDG) and 68Ga-ADAPT6 PET/CT scans before treatment. Based on immunohistochemistry and fluorescence in situ hybridization results， patients were categorized into HER2-high， HER2-low and HER2-zero expression groups. Clinical data and PET/CT metabolic parameters， including maximum standardized uptake value(SUVmax)， maximum standardized uptake value normalized by lean body mass (SULmax)， total lesion glycolysis and total HER2-targeted uptake were compared among groups. Spearman correlation analysis was used to assess the relationship between metabolic parameters and HER2 expression， and receiver operating characteristic curve analysis was employed to evaluate the discriminative ability of metabolic parameters for HER2 expression. ［Results］ Among the68Ga-ADAPT6 metabolic parameters， SUVmax in the HER2 high-expression group ［6.70(5.12， 12.39)］ was significantly higher than that in the HER2 low-expression group (4.65±2.27) and in the HER2 zero-expression group (3.34±1.59)with statistically significant differences (P<0.05)， SULmax in the HER2 high-expression group ［5.11 (3.67， 8.66)］ was significantly higher than that in the HER2 low-expression group (3.27±1.42) and in the HER2 zero-expression group (2.38±1.16) with statistically significant differences (P<0.05). However， no significant difference in SUVmax or SULmax was observed between the HER2-low and HER2-zero expression groups (all P>0.05). HER2 expression showed positive correlations with 68Ga-ADAPT6 SUVmax and SULmax (r=0.616， r=0.646， all P<0.001). The optimal cut-off value of 68Ga-ADAPT6 SUVmax for predicting HER2-high expression was 5.22， with a sensitivity of 80.0% and specificity of 75.0%. For SULmax， the optimal cut-off was 3.44， with a sensitivity of 70.0% and specificity of 91.7%.［Conclusion］ 68Ga-ADAPT6 PET/CT holds potential value for assessing HER2 status in breast cancer patients and may emerge as a promising imaging modality for screening candidates who could benefit from targeted therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |